Circle Pharma Raises $92.5 Million for Direct Cyclin D1 Inhibition
Circle Pharma closed an oversubscribed $92.5 million Series E led by The Column Group, with Nextech Invest, RA Capital Management, Euclidean Capital and a strategic investment from Eli Lilly. The company plans to advance…
